Reye Syndrome

Incidence prior to 1990: 0.3–0.6:100,000.

From 1987 to 1993: 0.03-0.06:100,000; 2 cases/y have been reported since 1994.

During early 1980s, an association between aspirin and Reye syndrome was recognized; thereafter, incidence declined dramatically. In 1986, a warning label on all aspirin-containing products was mandated in USA.

Surgery (all but life-or-death emergencies) contraindicated during Reye syndrome.

Following recovery, LFTs must be repeated.

Unrecognized inborn errors of metabolism that produce Reye-like syndromes, such as fatty-acid oxidation defects, carnitine deficiency, and amino and organic acidopathies

Recurrent liver dysfunction

Permanent neurologic sequelae